FDA Approves Eli Lilly's Lung Cancer Drug
November 24 2015 - 1:20PM
Dow Jones News
The U.S. Food and Drug Administration on Tuesday said it
approved Eli Lilly's drug to treat a form of the most common type
of lung cancer.
Portrazza can be used in combination with two forms of
chemotherapy to treat patients with advanced squamous non-small
cell lung cancer who haven't previously received medication
specifically for treating their advanced lung cancer. Portrazza, or
necitumumab, is a monoclonal antibody that blocks activity of EGFR,
a protein commonly found on squamous NSCLC tumors.
Lung cancer is the leading cause of cancer death in the U.S.,
with an estimated 221,200 new diagnoses and 158,040 deaths in 2015,
according to the FDA. The most common type of lung cancer,
non-small cell lung cancer, is further divided into two main types
named for the kinds of cells found in the cancer—squamous cell and
non-squamous cell.
"Lung cancer tumors can be varied, so treatment options need to
be tailored to the specific type of lung cancer in the patient,"
said Dr. Richard Pazdur, director of the Office of Hematology and
Oncology Products in the FDA's Center for Drug Evaluation and
Research.
He said the treatment approved Tuesday provides certain patients
a new option that may extend survival.
In a multicenter, randomized, open-label clinical study of 1,093
participants, patients who were taking Portrazza in combination
with chemotherapy were found to live an average of 11.5 months
compared with 9.9 months for patients who were only receiving
chemotherapy.
The most common side effects were skin rash and magnesium
deficiency, which can cause muscular weakness, seizure and
irregular heartbeats, and can be fatal. Risks include cardiac
arrest and sudden death.
Shares of Eli Lilly, up about 21% this year, were down 1.3% in
midday trading.
Write to Anne Steele at Anne.Steele@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 24, 2015 13:05 ET (18:05 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
